benzyl (5R,7S)-1-(3-fluorophenyl)-7-methyl-3-(pyrimidin-2-yl)-2-thia-1,3,8-triazaspiro[4.5]decane-8-carboxylate 2,2-dioxide | 1401249-78-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: benzyl (5R,7S)-1-(3-fluorophenyl)-7-methyl-3-(pyrimidin-2-yl)-2-thia-1,3,8-triazaspiro[4.5]decane-8-carboxylate 2,2-dioxide
• 英文别名: benzyl (5R,7S)-1-(3-fluorophenyl)-7-methyl-2,2-dioxo-3-pyrimidin-2-yl-2lambda6-thia-1,3,8-triazaspiro[4.5]decane-8-carboxylate；benzyl (5R,7S)-1-(3-fluorophenyl)-7-methyl-2,2-dioxo-3-pyrimidin-2-yl-2λ6-thia-1,3,8-triazaspiro[4.5]decane-8-carboxylate
• CAS: 1401249-78-2
• 化学式: C₂₅H₂₆FN₅O₄S
• 分子量: 511.577
• InChiKey: ZDNMQXBFDWURNA-UQBPGWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  104
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  benzyl (5R,7S)-1-(3-fluorophenyl)-7-methyl-3-(pyrimidin-2-yl)-2-thia-1,3,8-triazaspiro[4.5]decane-8-carboxylate 2,2-dioxide 在 Pd(OH)2/C 、 氢气 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、275.8 kPa 条件下， 生成 (5R,7S)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-3-(pyrimidin-2-yl)-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide
  参考文献：
  名称：

  Spirocyclic Sulfamides as β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer’s Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors

  摘要：

  beta-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention of Alzheimer's disease (AD). Herein, we describe the discovery of a novel class of BACE-1 inhibitors represented by sulfamide 14g, using a medicinal chemistry strategy to optimize central nervous system (CNS) penetration by minimizing hydrogen bond donors (HBDs) and reducing P-glycoprotein (P-gp) mediated efflux. We have also taken advantage of the combination of structure based drug design (SBDD) to guide the optimization of the sulfamide analogues and the in silico tool WaterMap to explain the observed SAR. Compound 14g is a potent inhibitor of BACE-1 with excellent permeability and a moderate P-gp liability. Administration of 14g to mice produced a significant, dose-dependent reduction in central A beta(X-40) levels at a free drug exposure equivalent to the whole cell IC50 (100 nM). Furthermore, studies of the P-gp knockout mouse provided evidence that efflux transporters affected the amount of A beta lowering versus that observed in wild-type (WT) mouse at an equivalent dose.

  DOI：

  10.1021/jm3009426
• 作为产物：
  描述：

  (S)-1-CBZ-2-甲基-4-哌啶酮 在 copper(l) iodide 、 氨 、 氢气 、 potassium carbonate 、 溶剂黄146 、 N,N'-二甲基乙二胺 、 3-(imidazole-1-sulfonyl)-1-methyl-3H-imidazol-1-ium triflate 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 20.0~105.0 ℃ 、344.75 kPa 条件下， 反应 30.0h， 生成 benzyl (5R,7S)-1-(3-fluorophenyl)-7-methyl-3-(pyrimidin-2-yl)-2-thia-1,3,8-triazaspiro[4.5]decane-8-carboxylate 2,2-dioxide
  参考文献：
  名称：

  Spirocyclic Sulfamides as β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer’s Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors

  摘要：

  beta-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention of Alzheimer's disease (AD). Herein, we describe the discovery of a novel class of BACE-1 inhibitors represented by sulfamide 14g, using a medicinal chemistry strategy to optimize central nervous system (CNS) penetration by minimizing hydrogen bond donors (HBDs) and reducing P-glycoprotein (P-gp) mediated efflux. We have also taken advantage of the combination of structure based drug design (SBDD) to guide the optimization of the sulfamide analogues and the in silico tool WaterMap to explain the observed SAR. Compound 14g is a potent inhibitor of BACE-1 with excellent permeability and a moderate P-gp liability. Administration of 14g to mice produced a significant, dose-dependent reduction in central A beta(X-40) levels at a free drug exposure equivalent to the whole cell IC50 (100 nM). Furthermore, studies of the P-gp knockout mouse provided evidence that efflux transporters affected the amount of A beta lowering versus that observed in wild-type (WT) mouse at an equivalent dose.

  DOI：

  10.1021/jm3009426